

Clinical Trial Protocol

Iranian Registry of Clinical Trials

10 Jun 2026

Evaluation of the effect of Deferasirox on MRIT2* and serum ferritin in major Thalassemia compared with Deferoxamine and Deferiprone in Gorgan Taleghani Hospital

Protocol summary

Summary

The aim of this study is evaluation of the effect of Deferasirox on MRIT2* and serum ferritin in major Thalassemia compared with Deferoxamine and Deferiprone in Gorgan Taleghani Hospital. In this study, 58 patients with major thalassemia who receive regular blood and serum ferritin levels below 5000 and treated with deferiprone with deferoxamine were randomly divided into 2 groups. in intervention group previous drug discontinue and treatment with Deferosyrox began. In control group continue previous drugs. At the beginning and end of one year, heart and liver MRI T2* and every three months serum ferritin level in all patients review. after one year, the result of this therapy on serum ferritin and cardiac and liver MRI T2* in patients with major thalassemia compared.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT2015071823245N1**

Registration date: **2015-11-12, 1394/08/21**

Registration timing: **retrospective**

Last update:

Update count: **0**

Registration date

2015-11-12, 1394/08/21

Registrant information

Name

Ghazal Vaseghi

Name of organization / entity

Golestan university of Medical Science

Country

Iran (Islamic Republic of)

Phone

+98 17 3254 0926

Email address

ghazal_vaseghi@yahoo.com

Recruitment status

Recruitment complete

Funding source

Research Center of Golestan University Medical Sciences

Expected recruitment start date

2014-10-23, 1393/08/01

Expected recruitment end date

2014-12-22, 1393/10/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Evaluation of the effect of Deferasirox on MRIT2* and serum ferritin in major Thalassemia compared with Deferoxamine and Deferiprone in Gorgan Taleghani Hospital

Public title

Effect of Deferasirox on ferritin and iron overload in Thalassemia Disease

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: Patients with major thalassemia with blood transfusions and treatment with Deferiprone with Deferoxamine; Ferritin levels below 5000ng/ml. Exclusion criteria: The patient dissatisfaction; drug intolerance.

Age

No age limit

Gender

Both

Phase

4

Groups that have been masked

No information

Sample size

Target sample size: 58

Randomization (investigator's opinion)

Not randomized

Randomization description

Blinding (investigator's opinion)

Not blinded

Blinding description

Placebo

Not used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

University ethics committee of Golestan University of Medical Sciences

Street address

Golestan University of Medical Sciences, beginning Shastkola road, 5 km Sari Gorgan road

City

Gorgan

Postal code

Approval date

2015-03-15, 1393/12/24

Ethics committee reference number

1107869312247

Health conditions studied

1

Description of health condition studied

major thalassemia

ICD-10 code

D56.9

ICD-10 code description

Thalassemia, unspecified

Primary outcomes

1

Description

serum ferritin

Timepoint

Baseline, 3 month, 6 month, 9 month, 12 month

Method of measurement

sampling and serum ferritin level (ng/ml)

2

Description

changes of MRI T2* normally, involves mild, moderate, severe

Timepoint

baseline, after one year

Method of measurement

MRI and The speed Back in phase T2* With millisecond and classify into four groups: normal, mild, moderate, severe

Secondary outcomes

empty

Intervention groups

1

Description

In the intervention group previous treatment will be discontinued and patient will be treated with Deferosirox 20-40 mg/ kg/ day for one year

Category

Treatment - Drugs

2

Description

The control group will be treated with Deferoxamine 20-60 mg/ kg/ day in three doses with or without of Deferiprone 50-100 mg/ kg/ day in three doses

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Gorgan Taleghani Hospital

Full name of responsible person

Ghazal Vseghi

Street address

Taleghani Hospital, Janbazan Blvd, Gorgan city, Golestan

City

Gorgan

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Research Center of Golestan University of Medical Sciences

Full name of responsible person

miss Nazari

Street address

Vice Chancellor for Research and Technology of
Golestan University of Medical Sciences, beginning of
Shastkola road, 5 km Sari Gorgan road

City

Gorgan

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Research Center of Golestan University of Medical
Sciences

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

empty

Person responsible for general inquiries**Contact****Name of organization / entity**

Golestan University of Medical Sciences

Full name of responsible person

Ghazal Vaseghi

Position

Resident of pediatrics

Other areas of specialty/work**Street address**

Taleghani hospital, Janbazan blvd., Gorgan

City

Gorgan

Postal code**Phone**

+98 17 3222 7720

Fax**Email**

ghazal_vaseghi@yahoo

Web page address**Person responsible for scientific inquiries****Contact****Name of organization / entity**

Golestan University of Medical Sciences

Full name of responsible person

Narges Beigom Mirbebahani

Position

Associate Professor

Other areas of specialty/work**Street address**

Taleghani Hospital, Janbazan blvd., Gorgan

City

Gorgan

Postal code**Phone**

+98 17 3222 7720

Fax**Email**

n.mirbebahani@gmail

Web page address**Person responsible for updating data****Contact****Name of organization / entity**

Taleghani Hospital

Full name of responsible person

Ghazal Vaseghi

Position

Resident of pediatrics

Other areas of specialty/work**Street address**

Taleghani hospital, Janbazan blvd, Gorgan

City

Gorgan

Postal code**Phone**

+98 17 3222 7720

Fax**Email**

ghazal_vaseghi@yahoo

Web page address**Sharing plan****Deidentified Individual Participant Data Set (IPD)**

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty